ASX Announcement

MAYNE PHARMA AGM UPDATES

16 November 2026, Adelaide, Australia: Mayne Pharma Group Limited (Mayne Pharma or the Company) (ASX: MYX) refers to its notice of meeting (**Notice of Meeting**) and proxy form dispatched on 19 October 2026 for its Annual General Meeting scheduled for 10am (Melbourne time) on Friday, 20 November 2026 (**AGM**). The Company provides the updates below in relation to the AGM.

Resolution 4 – Election of Dr Brett Wells

Despite Dr Brett Wells being asked on multiple occasions by Mayne Pharma since his nomination to be a director of the Company to consent as needed to permit Mayne Pharma to undertake customary and ASX Corporate Governance Council recommended background checks, Dr Wells only provided his consent at 12.52am on Sunday, 15 November 2026.

As a result of Dr Wells' lengthy delay in providing his consent to the background checks, Mayne Pharma may not have sufficient time to complete those checks and determine whether anything material about Dr Wells' background should be disclosed to shareholders before they lodge their proxies or vote on his election at the AGM.

Appointment of two proxies

Paragraph 2 under the heading 'Proxies and Shareholder Information' on the page numbered 6 of the Notice of Meeting is replaced with the following:

> *If a Shareholder is entitled to cast two or more votes, they may appoint two proxies (but no more) and may specify the proportion or number of votes each proxy is appointed to exercise. If the appointment does not specify the proportion or number of votes each proxy may exercise, each proxy may exercise half of the votes, with fractions disregarded. If a Shareholder appoints two proxies, neither proxy may vote on a show of hands.*

Proxy form

Under the heading 'Step 2 Items of Business' on the proxy form, the shaded note states (emphasis added):

> *'Please Note: If the Chair of the Meeting is appointed as your proxy (or becomes your proxy by default), the Chair of the Meeting intends to vote available proxies in the manner set out beside each resolution. This reflects the Board's recommendation.'*

The reference to 'available proxies' in that statement refers to the Chair's voting intention with respect to 'undirected' proxies.

As noted on the proxy form, the shaded 'For' and 'Against' statements beside each resolution on the form represent the Board's recommendations with respect to each of those resolutions. Shareholders may still vote 'For', 'Against' or 'Abstain' in relation to those resolutions.

- ENDS -

Mayne Pharma Group Limited
ABN 76 115 832 963
maynepharma.com
1538 Main North Road, Salisbury South, SA 5106 Australia

For further information contact:

Dr Tom Duthy
Investor Relations
+61 402 493 727
ir@maynepharma.com

Authorised for release to the ASX by the Board Chair.

Follow us on LinkedIn

About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne Pharma is a leader in dermatology and women's health in the United States and also provides contract development and manufacturing services to clients worldwide. Mayne Pharma has a 40-year track record of innovation and success in developing new oral drug delivery systems. These technologies have been successfully commercialised in numerous products that continue to be marketed around the world. To learn more about Mayne Pharma, please visit maynepharma.com.